Active substanceCeftriaxoneCeftriaxone
Similar drugsTo uncover
  • Azaran
    powdersolution w / m in / in 
    Hemofarm AD     Serbia
  • Axon
    powder w / m in / in 
  • Betasporin
    powdersolution w / m in / in 
    Laboratorios Atral SA     Portugal
  • Biotrakson
    powdersolution w / m in / in 
  • Broadssef-S
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • IFICEF®
    powder w / m in / in 
  • Lendacin®
    powder d / infusion 
    Lek dd     Slovenia
  • Lifaxon
    powdersolution w / m in / in 
    FARMGID CJSC     Russia
  • Medaxon
    powder w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Movigip®
    powder w / m in / in 
  • Oframax®
    powdersolution w / m in / in 
  • Rocefin®
    powder w / m 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder in / in 
  • Rocefin®
    powder w / m in / in 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
  • Steritsef®
    powdersolution for injections 
  • Tertsef®
    powdersolution w / m in / in 
    Aktavis, AO     Iceland
  • TOROCEF®
    powdersolution w / m in / in 
  • Triacson
    powdersolution w / m in / in 
  • Chizon
    powdersolution w / m in / in 
    Shin Pung Pharmaceutical Co., Ltd.     The Republic of Korea
  • Cefaxon
    powdersolution w / m in / in 
    Lupine Co., Ltd.     India
  • Cefatrine
    powdersolution w / m in / in 
  • Cefogram®
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriaxone
    powdersolution d / infusion 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Ceftriaxone
    powdersolution w / m in / in 
    RUZFARMA, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    RAFARMA, CJSC     Russia
  • Ceftriaxone
    powdersolution
    Mapichem AG     Switzerland
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    LEKKO, ZAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    Vertex Exports     India
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOCHEMIST, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution
    SYNTHESIS, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    Company DEKO, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    MAKIZ-PHARMA, LLC     Russia
  • Ceftriaxone
    powder w / m in / in 
    HIMFARM, JSC     Kazakhstan
  • Ceftriaxone
    powder w / m in / in 
  • Ceftriaxone Danson
    powdersolution w / m in / in 
  • Ceftriaxone DS
    powdersolution
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Protek
    powdersolution w / m in / in 
  • Elf Ceftriaxone
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Ceftriaxone-Vial
    powdersolution w / m in / in 
    VIAL, LLC     Russia
  • Ceftriaxone-Jodhas
    powdersolution w / m in / in 
  • Ceftriaxone-CmP
    powdersolution w / m in / in 
  • Ceftriaxone-LEXMM®
    powdersolution w / m in / in 
  • Dosage form: & nbsppowder for solution for intravenous and intramuscular administration
    Composition:
    Active substances:
    Ceftriaxone (ceftriaxone sodium trisesquihydrate) - 1000.0 (1193.0) mg
    Sulbactam (sulbactam sodium) - 500.0 (547.0) mg
    Description:The fine crystalline powder is white or almost white in color.
    Pharmacotherapeutic group:Antibiotic-cephalosporin + beta-lactamase inhibitor
    ATX: & nbsp

    J.01.D.D.04   Ceftriaxone

    Pharmacodynamics:
    Combined drug.
    Ceftriaxone is a nilusynthetic cephalosporin antibiotic of the third generation of a broad spectrum of action.
    The bactericidal activity of ceftriaxone is due to the suppression of the synthesis of cell membranes.
    Sulbactam is a derivative of the main nucleus of penicillin. It is an irreversible inhibitor of beta-lactamases, which are released by microorganisms resistant to beta-lactam antibiotics; prevents the destruction of penicillins and cephalosporins under the action of beta-lactamases of resistant microorganisms; by binding to penicillin-binding proteins,shows synergy with simultaneous application with penicillins and cephalosporins.
    Sulbactam has no clinically significant antibiotic activity (except Neisscriaccae and Acinetobaceer some penicillin binding proteins, so the combination ceftriaxone+ [sulbactam] often has a more pronounced effect on sensitive strains than one ceftriaxone.
    Combination ceftriaxone+ [Sulbactam] active against all microorganisms susceptible to ceftriaxone and acts synergistically (decreases to 4 times the minimum inhibitory concentration (MIC) of the combination compared with ceftriaxone). It is active against the following microorganisms:
    Gram-negative aerobes: Acinetobacter lwoffii, Acinctobacler anitratus *, Aeromonas hydrophila, Alcaligenes faccalis, Alcaligenes odorans, Borrelia burgdorferi, Capnocytophaga spp., Citrobacter diversus, Citrobacter freundii **, Escherichia coli, Entcrobacter aerogenes *, Enterobacter cloacae *, Enterobacter spp. *, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Hafnia alvei, Klebssiella oxytoca, Klebssiella pneumoniae *, Moraxella catarrhalis, Moraxella osloensis, Moraxella spp., Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Plesiomonas shigelloides, Proteus mirabilis, Proteus vulgaris *, Proteus penneri *, Pseudomonas fluorences *, Pseudomonas spp., Providencia spp., including Providencia rettgeri *, Salmonella spp. (non-typhoid), Salmonella typhi, Serratia spp. *, incl. Serratia marcescens *, Shigella spp .. Vibrio spp., Yersinia spp., In t.ch.Yersinia enterocolitica.
    * Some isolates of these species are resistant to ceftriaxone, mainly due to the formation of beta-lactamases, encoded by chromosomes.
    * * Some isolates of these species are resistant to ceftriaxone due to the formation of a number of plasmid-mediated beta-lactamases.
    A number of strains of the above microorganisms that exhibit resistance to other antibiotics, such as penicillins, cephalosporins, aminoglycosides, are sensitive to ceftriaxone. Treponema pallidum is sensitive to ceftriaxone in vitro. Clinical strains of Pseudomonas aerugenosa are resistant to ceftriaxone.
    Gram-positive aerobes:
    Staphylococcus aureus (including strains forming penicillinase), Staphylococcus spp. (coagulase-negative), Streptococcus pyogenes (group A beta-hemolytic streptococci), Streptococcus agalactiae (group B beta-hemolytic streptococci), Streptococcus pneumoniae, Streptococcus spp. group of viridians.
    Note: methicillin-resistant Staphylococcus spp. resistant to cephalosporins, incl. to ceftriaxone. As a rule, Enterococcus faccalis, Enterococcus faecium and Listeria monocytogenes are also stable.
    Anaerobic microorganisms:
    Bacteroides spp. (bile-sensitive) *, Clostridium spp. (except Clostridium difficile), Fusobacterium spp. (including Fusobacterium nucleatum), Peptococcus spp., Peptostreptococcus spp.
    * Some isolates of these species are resistant to ceftriaxone because of the formation of beta-lactamases.
    Pharmacokinetics:
    The maximum concentration (Cmax) of ceftriaxoa after a single intramuscular (IM) dose of 1.0 g is approximately 81 mg / L, and is achieved 2-3 hours after administration, while in the sulbactam it is 6.24 mg / l, and is achieved approximately 1 hour after administration.
    The area under the pharmacokinetic curve "concentration-time" (AUC) for csrtriaxone after IM is the same as after intravenous (iv) administration of an equivalent dose, indicating 100% bioavailability after IM. The volume of csltriaxone distribution is 7-12 liters, and the sulbactam is 18-27.6 liters. Ceftriaxone and sulbactam is distributed well in various tissues and body fluids, including ascynic fluid, cerebrospinal fluid (in patients with inflammation of the meninges), urine, saliva, tonsils, skin, fallopian tubes, ovaries, uterus, lungs, bones, bile, gall bladder, appendix. The drug penetrates the placental barrier.
    Ceftriaxone by 70-90%, sulbactam by 38% reversibly bind to plasma proteins. Ceftriaxone is not subject to systemic metabolism, but turns into inactive metabolites under the influence of intestinal microflora.
    Half-life (T1 / 2) of sulbactam averages about 1 hour, ceftriaxone is about 8 hours. Plasma clearance of ceftriaxone - 10-20 ml / min, renal clearance - 5-12 ml / min.
    Approximately 84% of the dose of sulbactam and 50-60% of the dose of ceftriaxone are excreted by the kidneys unchanged, the rest of the ceftriaxone is excreted with bile into the intestine.

    With repeated application of significant changes in the pharmacokinetic parameters of both components of the drug was not noted. With the introduction of the drug every 8-12 hours no cumulation was observed.

    Penetration into the cerebrospinal fluid: in newborns and in children with inflammation of the meninges ceftriaxone penetrates into the cerebrospinal fluid, while in the case of bacterial meningitis, on average 17% of the concentration of ceftriaxone in the plasma diffuses into the cerebrospinal fluid, which is approximately 4 times greater than in aseptic meningitis. 24 hours after intravenous administration of ceftriaxone in a dose of 50-100 mg / kg body weight, concentrations in the cerebrospinal fluid exceed 1.4 mg / l. In adults with meningitis, 2-24 hours after the administration of 50 mg / kg of body weight, the concentration of ceftriaxone in the cerebrospinal fluid is many times greater than the minimal inhibitory concentrations for the most common meningitis pathogens.

    Special patient groups

    In neonates, about 70% of the injected dose of ceftriaxone is excreted by the kidneys. In children in the first 8 days of life, as well as in people older than 75 years, T1 / 2, on average, 2-3 times greater than in adults.

    In patients with impaired renal or hepatic function, the pharmacokinetics of ceftriaxone varies only slightly, with only a slight increase in T1 / 2. If the kidney function is impaired, the excretion of bile increases, if the function of only the liver is impaired, the excretion by the kidneys increases.

    In patients with varying degrees of renal dysfunction, a high correlation was found between the total clearance of sulbactam from the body and the estimated clearance of creatinine. In patients with terminal renal failure, a significant lengthening T1/2 sulbactam (up to 9.7 hours). Hemodialysis caused significant changes in the half-life, total clearance and volume of distribution of sulbactam.

    Indications:
    Infectious-inflammatory diseases caused by pathogens sensitive to the combination of ceftriaxone and sulbactam:
    - infections of the kidneys and urinary tract;
    - infections of the abdominal cavity (peritonitis, biliary tract infections and gastrointestinal tract);
    - infections of the lower respiratory tract (including pneumonia);
    - septicemia;
    - infection of LOP-organs (including acute otitis media);
    - bacterial meningitis;
    - infection of bones, joints;
    - infections of the skin and soft tissues (incl.wound infections);
    - Lyme disease;
    - infection of the genitals, including uncomplicated gonorrhea.
    Infectious diseases in patients with reduced immunity. Prevention of postoperative infections.
    Contraindications:Hypersensitivity to sulbactam and ceftriaxone, as well as to other cephalosporins, penicillins, beta-lactam antibiotics; Hyperbilirubinemia or jaundice in term infants; premature newborns under the "expected" age of 41 weeks (including the term of intrauterine development and age); term infants who are shown intravenous administration of calcium-containing solutions; acidosis, hypoalbuminemia in full-term newborns.
    Carefully:With ulcerative colitis, with violations of the liver and kidneys, with enteritis and colitis associated with the use of antibacterial drugs.
    Pregnancy and lactation:
    The use of the drug during pregnancy is possible only in those cases when the intended use for the mother exceeds the potential risk to the fetus (ceftriaxone and sulbactam penetrate the placental barrier).
    If you need to use the drug during lactation, you should decide whether to stop breastfeeding.
    Dosing and Administration:

    The drug is administered parenterally: intramuscularly or intravenously.

    Adults and children over 12 years of age: the usual dose is 1-2 g of ceftriaxone (0.5-1 g of sulbactam) once a day or divided into two injections (every 12 hours).

    In severe cases or infections, the causative agents of which have only moderate sensitivity to ceftriaxone, the daily dose can be increased to 4 g.

    The maximum daily dose of sulbactam is 4 g. The duration of treatment depends on the course of the disease. As always with antibiotic therapy, the administration of Broadsef-S should be continued for at least 48-72 hours after the temperature is normalized and the eradication of the pathogen is confirmed. The course of treatment is usually 4-14 days; with complicated infections, a longer duration of administration may be required. The course of treatment for infections caused by Streptococcus pyogenes, must be at least 10 days.

    In patients with impaired renal function There is no need to reduce the dose if the liver function remains normal.In chronic renal failure (CC less than 15 ml / min) - the daily dose should not exceed 2 g of ceftriaxone and 1 g of sulbactam.

    In patients with hepatic dysfunction there is no need to reduce the dose if the kidney function remains normal.

    When combination of renal and hepatic insufficiency should regularly determine the concentration of ceftriaxone in the plasma and, if necessary, adjust its dose. The daily dose should not exceed 2 g without determining the concentration of ceftriaxone in the blood plasma.

    Patients on hemodialysis do not require an additional dose after a hemodialysis session, however, it is necessary to control the concentration of ceftriaxone in the plasma, since its excretion in such patients can be slowed down (dose adjustment may be required).

    Elderly patients: usual doses for adults, without adjustments for age.

    Children under 12 years old

    When using the drug once a day, it is recommended to adhere to the following dosing regimens:

    Newborns (up to 2 weeks): 20-50 mg / kg body weight ceftriaxone (10-25 mg / kg sulbactam) once a day. The daily dose of ceftriaxone should not exceed 50 mg / kg of body weight.

    Newborns, infants and young children (from 15 days to 12 years): the recommended daily dose of ceftriaxone is 20-80 mg / kg (10-40 mg / kg sulbactam) once a day or divided into 2 divided doses (every 12 hours). The total daily dose of ceftriaxone in children should not exceed 2 g; the maximum daily dose of sulbactam should not exceed 80 mg / kg. A dose of 50 mg / kg body weight and more (ceftriaxone) should be given as an IV infusion within 30 minutes. When treatment of acute otitis media in children is recommended a single I / m injection at a dose of 50 mg / kg (but not more than 1 g).

    In children with a body weight of 50 kg or more, doses for adults are used.

    Bacterial meningitis

    For bacterial meningitis in infants and young children, treatment starts with a dose of 100 mg / kg ceftriaxone (but not more than 4 g) once a day (50 mg / kg sulbactam, but not more than 2 g). After identifying the pathogen and determining its sensitivity, the dose can be reduced accordingly. The best results with meningococcal meningitis were achieved with a treatment duration of 4 days, with meningitis caused by Haemophilus influenzae - b days, Streptococcus pneumoniae - 7 days.

    Lyme disease (borreliosis): adults and children - 50 mg / kg (the highest daily dose - 2 g) ceftriaxone once a day for 14 days.

    Uncomplicated gonorrhea - a single intravenous injection of 250 mg (ceftriaxone).

    Prevention of postoperative infections, depending on the degree of infectious risk, 1-2 g of ceftriaxone (0.5-1 g of sulbactam) is administered once for 30-90 min before the start of the operation. In operations on the colon and rectum, simultaneous (but separate) administration of ceftriaxone / sulbactam and one of the drugs from the 5-nitroimidazoles group was well established.

    Rules for the preparation and administration of solutions: Use only freshly prepared solutions.

    For intramuscular injection: the contents of the vial (1.5 g) are dissolved in 3.5 ml of water for injection or 1% solution of lidocaine. After preparation, each ml of the solution contains about 250 mg in terms of ceftriaxone.

    If necessary, a more dilute solution may be used. As with other intramuscular injections, the drug is injected into a relatively large muscle; Trial aspiration helps to avoid unintentional insertion into the blood vessel. It is recommended to inject no more than 1000 mg of ceftriaxone (500 mg of sulbactam) into one relatively large muscle. Do not inject a solution containing lidocaine, intravenously.

    For intravenous administration: the contents of the vial are dissolved in 10 ml of water for injection. After preparation, each ml of the solution contains about 100 mg in terms of ceftriaxone. The solution is administered slowly for 2-4 minutes.

    For intravenous infusion dissolve 2 g of ceftriaxone (1 g of sulbactam) in 40 ml of one of the following solutions that do not contain calcium (0.9% sodium chloride solution, 5% or 10% dextrose solution, 6% dextrin solution in 5% dextrose solution). The solution is introduced for 30 minutes.

    Side effects:

    Allergic reactions: fever or chills, anaphylactic or anaphylactoid reactions (eg bronchospasm), rash, itching, allergic dermatitis, urticaria, edema, exudative erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome, allergic pneumonitis, serum sickness.

    From the nervous system: headache, dizziness, convulsions, vertigo.

    From the gastrointestinal tract: abdominal pain, diarrhea, nausea, vomiting, taste disorder, dyspepsia, bloating, stomatitis, glossitis, pancreatitis, pseudomembranous colitis.

    Disorders from the liver and bile ducts: cholelithiasis, a "sluggish phenomenon" of the gallbladder, jaundice.

    From the side of the blood and lymphatic system: anemia (including hemolytic), leukopenia, lymphopenia, leukocytosis, lymphocytosis, monocytosis, neutropenia, thrombocytopenia, thrombocytosis, eosinophilia, granulocytopenia, basophilia, increase (decrease) in prothrombin time, increase in thromboplastin time, agranulocytosis.

    Disorders from the kidneys and urinary tract: mycoses of genital organs, oliguria, vaginitis, iesfrolithiasis.

    Local reactions: when in / in the introduction - phlebitis, tenderness, densification of the veins; Intramuscular injection - soreness, sensation of warmth, tightness or condensation at the injection site.

    Laboratory indicators: increased activity of "liver" transaminases and alkaline phosphatase, hyperbilirubinemia, hypercreatininemia, increased urea concentration, the presence of sediment in the urine, glucosuria, hematuria.

    Other: increased sweating, "hot flashes" of blood, nosebleeds, a feeling of palpitations, the formation of precipitates in the lungs.

    Overdose:
    Symptoms: neurological disorders, including convulsions.
    Treatment: overdose treatment is symptomatic.There is no specific antidote.
    In case of an overdose of hemodialysis and peritoneal dialysis, ceftriaxone concentrations will not decrease.
    Interaction:
    Bacteriostatic antibiotics reduce ceftriaxone / sulbactam. Antagonism with chloramphenicol in vitro.
    Pharmaceutical interaction
    The ceftriaxone / sulbactam solution should not be mixed or administered concomitantly with other antimicrobial agents. Pharmaceutically incompatible with solutions containing calcium ions (including Hartman and Ringer's solution) - precipitates may form; as well as with amsacrine, vancomycin, fluconazole and aminoglycosides. Ceftriaxone does not contain N-methylthiotetrazol group, therefore, simultaneous use with ethanol does not lead to the development of disulfiram-like reactions inherent in some cephalosporins.
    With the simultaneous use of large doses of ceftriaxone and loop diuretics (eg, furosmide), renal dysfunction was not observed. There are no indications that tsftfriakson increases the nephrotoxicity of aminoglycosides. Probenecid does not affect the excretion of ceftriaxone.
    Ceftriaxone and aminoglycosides have a synergistic effect on many Gram-negative bacteria.Although the increased efficacy of such combinations is not always predictable, it should be borne in mind in severe, life-threatening infections, such as those caused by Pseudomonas aeruginosa. Ceftriaxone reduces the effectiveness of oral contraceptives, therefore it is recommended to use additional non-hormonal contraceptives. The formation of precipitates of calcium salts of ceftriaxone can also occur when the preparation and calcium-containing solutions are mixed using one venous access. Do not use the drug simultaneously with calcium-containing solutions for intravenous administration, including long-term infusions of calcium-containing solutions, for example, with parenteral nutrition using the Y-connector. For all groups of patients, except for newborns, it is possible to consistently administer the preparation and calcium-containing solutions with thorough washing of the infusion systems between infusions of a compatible liquid.
    Special instructions:Patients receiving beta-lactam antibiotics, such as cephalosporins, have reported cases of severe reactions of hypersensitivity (anaphylactic).The risk of hypersensitivity reactions, including those leading to death, is higher in patients who have a history of hypersensitivity reactions to many allergens. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy.
    Serious anaphylactic reactions require urgent epinephrine. Intravenously injected glucocorticosteroids and provide airway patency, including intubation.
    With the simultaneous use of aminoglycosides, it is necessary to monitor kidney function. When concomitant severe renal and hepatic failure, as well as in patients on hemodialysis, should be regularly to determine the concentration of drug in plasma.
    With long-term treatment, it is necessary to regularly monitor the picture of peripheral blood, indicators of the functional state of the liver and kidneys.
    In rare cases, gallbladder marked darkening (precipitates the calcium salt of ceftriaxone) by ultrasound (US), which disappear after cessation of treatment. With the development of symptoms or signs indicating a possible gallbladder disease,or if there are ultrasound signs of a "sluggish phenomenon," it is recommended that the drug be discontinued.
    When using the drug, rare cases of pancreatitis, which developed, possibly, as a result of obstruction of the biliary tract, are described. Most patients had risk factors for congestion in the biliary tract (previous drug therapy, severe co-morbidities, complete parenteral nutrition); However, the starting role of precipitate formation in the biliary tract under the influence of ceftriaxone can not be ruled out. When using ceftriaxone, rare cases of prothrombin time change are described. Patients with vitamin K deficiency (impaired synthesis, eating disorders) may need to monitor prothrombin time and prescribe vitamin K (10 mg / week) with an increase in prothrombin time before or during therapy. Cases of fatal reactions as a result of deposition of ceftriaxone-calcium precipitates in the lungs and kidneys of newborns are described. Theoretically there is a probability of interaction of ceftriaxone with calcium-containing solutions for intravenous administration and in other age groups of patients, therefore ceftriaxone should not be mixed with calcium-containing solutions (incl.for parenteral nutrition), and also introduced simultaneously, incl. through separate accesses for infusions at different sites. Theoretically, based on the calculation of 5 ceftriaxone, the interval between the administration of ceftriaxone and calcium-containing solutions should be at least 48 hours. Data on the possible interaction of ceftriaxone with oral calcium-containing preparations, as well as ceftriaxone for intramuscular administration with calcium-containing drugs (IV and oral) are absent.
    In the treatment of ceftriaxone, false-positive results of Coombs test, a test for galactosemia, glucose in urine (glucosuria is recommended to be determined only by enzyme method).
    When using the drug, both in the background of taking, and after 2-3 weeks. after discontinuation of treatment, the development of diarrhea caused by Clostridium difficile (pseudomembranous colitis) is possible. In mild cases, it is sufficient to cancel the treatment and apply ion-exchange resins (colestramine, colestipol), in severe cases, compensation for loss of fluid, electrolytes and protein, the appointment of vancomycin and metronidazole inside. Do not use drugs that inhibit the intestinal peristalsis.When using ceftriaxone (as well as other antibiotics), the development of superinfection is possible, which requires the withdrawal of the drug and the appointment of appropriate treatment. Ceftriaxone can displace bilirubin from association with serum albumin. As with the use of other cephalosporins, the development of autoimmune hemolytic anemia is possible with drug treatment. Cases of severe hemolytic anemia in adults and children, including fatal cases, have been reported. In case of anemia, therapy with the drug should be discontinued.
    Effect on the ability to drive transp. cf. and fur:Given the profile of unwanted reactions, during the treatment period, care must be taken when driving vehicles, working with mechanisms and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.
    Form release / dosage:
    Powder for solution for intravenous and intramuscular injection 1 g + 0.5 g.
    Packaging:The amount of the preparation corresponding to 1 g of ceftriaxone and 0.5 g of sulbactam in a vial of clear, colorless glass, corked with a rubber stopper,Crimped with an aluminum cap with a plastic cover for the first autopsy. 1 bottle per pack of cardboard along with instructions for use.
    Storage conditions:In the dark place at a temperature of no higher than 25° FROM. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-002913
    Date of registration:16.03.2015 / 07.08.2015
    Expiration Date:16.03.2020
    The owner of the registration certificate:ELFA NPC, CJSC ELFA NPC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.02.2017
    Illustrated instructions
      Instructions
      Up